Christina Johnson to Male
This is a "connection" page, showing publications Christina Johnson has written about Male.
Connection Strength
0.116
-
An orthotopic bladder cancer model for gene delivery studies. J Vis Exp. 2013 Dec 01; (82):50181.
Score: 0.012
-
Inner ear supporting cells protect hair cells by secreting HSP70. J Clin Invest. 2013 Aug; 123(8):3577-87.
Score: 0.012
-
TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol. 2011 Jun 14; 8(8):417-27.
Score: 0.010
-
Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer Biol Ther. 2009 Jan; 8(1):81-3.
Score: 0.009
-
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med. 2007 Nov 01; 43(9):1313-21.
Score: 0.008
-
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007 Mar; 14(3):327-34.
Score: 0.007
-
Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol Ther. 2006 Dec; 5(12):1618-23.
Score: 0.007
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.007
-
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
Score: 0.007
-
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005 Jan 07; 5:2.
Score: 0.006
-
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther. 2003 May-Jun; 2(3):283-90.
Score: 0.006
-
Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 2002 Sep-Oct; 1(5):520-7.
Score: 0.005
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.005
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.005
-
Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther. 2000 Oct; 2(4):348-58.
Score: 0.005
-
Genomic instability-based transgenic models of prostate cancer. Carcinogenesis. 2000 Aug; 21(8):1623-7.
Score: 0.005